A Priori Activation of Apoptosis Pathways of Tumor often referred to as "AAAPT" is a novel targeted tumor sensitizing technology which synergizes with chemotherapy to enhance the treatment efficacy.
Introduction
Tumor cells have a remarkable ability to circumvent endogenous and exogenous toxicities by deactivating cell death pathways and thereby desensitizing themselves to interventions 1 . Defects in apoptosis pathways (e.g. CD95, APO-1/Fas) would make tumor cells insensitive to chemotherapy 2 . For example, loss of CD95 signaling pathway resulted in the development of cancer 3 and resistance to chemotherapy 4 . Restoration of the apoptotic machinery with apoptosis inducing ligands (apoptogens) is an area of active investigation in the drug development. Several agents have been developed to activate TRAIL 5 , to downregulate Bcl-2 6 and to restore the function of the mutated p53 in order to sensitize tumor cells. Similarly, new advances in the molecular biology of cancer cells reveal that cancer stem cells (CSCs) and cancer resistant cells (CRCs) escape cell death by activating the survival pathway (e.g. NF-kB) and by hyperacting DNA repair enzyme Poly ADP ribose polymerase (PARP) which repairs DNA breaks caused by oncology drugs. Tumor sensitizing technology, specifically for CSCs and CRCs may have to consider offsetting these pathways. A better response from the existing treatments means reducing the therapeutic dose without compromising efficacy and thus, reduce the dose related off-target toxicity. Consequently, tumor sensitizers, potentially can be used as neoadjuvant to chemotherapy to expand the therapeutic index of chemotherapy 7 .
Tumor sensitivity to chemotherapy in vivo is shown to be dependent on spontaneous baseline tumor apoptosis index 8 . Aggressive or incurable cancers show low tumor apoptosis index (AI) and low sensitivity to chemotherapy compared to benign cancer 9 . In fact, the spontaneous levels of apoptosis are strong predictor of treatment response 10 . For example, low baseline apoptosis index (AI) of patient tumors (see Fig 4 in ref 9 ), is directly correlated to non-respondent patients to chemotherapy ((> 67%). Lower the baseline apoptosis index of tumor, least the response from chemotherapy and vice versa (Fig 3 in ref 2) . The overall 5-year survival rates for the patient group with high AI (> 0.97) and low AI (< 0.97, p =0.001) were 89.6 % and 69.2 % respectively 11 indicating that AI could be a potential biomarker of risk stratification of tumors/patients to see who responds better to which treatments if AAAPT technology goes to clinical level.
We have developed a novel technology, "A priori Activation of Apoptosis Pathways of Tumor" (AAAPT) as a strategy to sensitize low responsive tumor cells in order to evoke a better response from chemotherapy 12 . The goal is to understand the molecular biology of desensitization tactics of tumor cells which bypass the intervention by reactivating specific dysregulated cell death pathways and inhibiting survival pathways simultaneously and selectively in tumor cells sparing normal cells. Since ubiquitous or systemic activation of apoptosis can induce undesirable neurodegeneration and myelosupression 13 , targeting is essential 14 .
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer for which no targeted therapy is approved so far due to lack of biomarkers (ER, PR and HER2 negative) based on which drugs are designed 15 . About 90 % of TNBC patients experience metastatic recurrence within 3-5 years with a median survival of just 13 months 16 . Most front-line treatments for TNBC patients including anthracycline drugs despite they induce cardiotoxicity. Loss of cardiomyocytes cannot be replaced since they do not replicate easily. Hence, it is an unmet medical need to improve the clinical performance of current treatments that lowers the off-target toxicity including cardiotoxicity using new tumor sensitizing technology, particularly for TNBC patients who have limited options of treatment, except chemotherapy. Thus, adjuvant or perioperative chemotherapy and molecule-targeted chemotherapy have been in clinical trials for controlling metastasis, reducing cancer recurrence and increasing overall survival 16b . TNBC cells are also known to downregulate CD95 pathway which makes them insensitive to chemotherapy 17 . Hence, we investigate the tumor sensitizing potential of leading AAAPT molecules AMP-001/003 in TNBC cells to evoke a better response or synergistic effect with a standard chemotherapy for example, doxorubicin. Doxorubicin (dox) is a first-line of treatment which is widely used in clinical therapeutic regimens for a variety of cancers including TNBC. Nevertheless, the clinical application is limited due to the drug resistance and adverse effects, including cardiomyopathy, typhlitis, and acute myelotoxicity 18 . To decrease dox-induced dose-dependent toxicity, enhancing the effective therapeutic index via combination with nontoxic or selective apoptotic inducing ligands has been investigated. Here, we propose novel targeted tumor sensitizers which address how the cancer cells circumvent interventions by reactivating cell death pathways and inhibiting survival pathways simultaneously. Since desensitization tactics by cancer cells are successful in thwarting the efficacy of treatments, a fundamental reversal of cancer cells tactics may have high impact on several modes of interventions (e.g. chemotherapy, radiation and immunotherapy).
Here, we report to demonstrate the synergistic effect of AMP-001-003 with front line chemotherapeutics in vitro and in vivo in a TNBC animal model.
Rational Drug Design:
The drug design AMP-001 involves pegylation of -tocopheryl succinate (apoptogen) with a dipeptide linker valine-citrulline (VC) which is cleavable by tumor specific Cathepsin B enzyme giving rise to a biologically active final molecule (Scheme 1). We have also synthesized VC conjugated -tocopherol as a pro-drog with ether linkage (AMP-002) or ester linkage (AMP-003). AMP-002 and AMP-003 are designed without pegylation, yet cleavable by tumor specific enzyme Cathepsin B. This design provided impetus for a) targeting apoptogen to cancer cells using tumor specific biomarker Cathepsin B 19 sparing normal cells, b) releasing the drug near tumor sites through the release of the biological component by cleaving at valinecitrulline link , c) pegylation to make it water soluble, d) enhancing the bioavailability of AMP-001and e) to keep it intact as a pro-drug in blood circulation for a long time to reach tumor sites.
The rationale behind using cathepsin B cleavable linkers is based on the better safety profile of Cathepsin B cleavable prodrugs doxorubicin 20a , paclitaxel 20b and antibodies 20c (Seattle Genetics) compared to unmodified drugs. Cathepsin B is known to a) be a tumor specific biomarker and b) cleave valine-citrulline substrate 21 . For example, high delineation of tumor from the surrounding tissues by cathepsin B sensitive optical probes 22 shows that this enzyme is restricted to invading cancers.
Although, parent molecule -tocopheryl succinate (-TOS) showed promising anti-tumor properties in vitro, studies in an immunocompetent mouse in vivo model showed that -TOS was not only ineffective at the published doses, but resulted in severe side effects due to lack of targeting 23 . Elevated ROS levels have to be achieved selectively in cancer cells which can render them sensitive to agents that cause oxidative stress [24] [25] . There are several chemotherapeutics 26 which may augment ROS without selectivity leading to non-specific side effects. Hence, targeting is essential.
Here, we examined the effect of combining AMP-001 and doxorubicin for a potential synergistic effect in TNBC both in vitro and in vivo. These results indicate that low dose pretreatment of tumor in vivo prepares tumor to make it sensitive to doxorubicin by showing a cumulative and significant tumor regression compared to individual drugs. A potential mechanism of action is being suggested based on the limited data.
Materials and Methods

Cell Culture and Treatment
The TNBC cell lines MDA-MB-231 and MCF-7 were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin in a humidified atmosphere with 5% CO 2 at 37℃.
NF-kB Inhibition Assay:
MDA-MB-231 TNBC cells (5x10 -5 cells/well) were seeded in 6-well plate and allowed to attach overnight, and treated with tocopheryl succinate (50 µM) or AMP-001/002/003 (20 µM) for 24 h. Alternatively, cells were incubated with the agents (4 h) and NF-kB pathway was activated by TNF-alpha (50 ng/ml) for 30 min. After treatment, cells were harvested, and the pellet re-suspended in the cytoplasm extract (CE) buffer (10 mM HEPES, 60 mM KCl, 1 mM EDTA, 0.075% (v/v) NP40, 1mM DTT and 1 mM PMSF, adjusted to pH 7.6). After 5 min incubation on ice, the pellet was centrifuged at 1500 rpms for 5 min, and the supernatant containing the cytosolic fraction was collected. The remaining pellet was washed in CE buffer, and lysed in the nuclear extract (NE) buffer (20 mM Tris-HCl, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM PMSF and 25% (v/v) glycerol, adjusted to pH 8.0). After 20 min incubation on ice, the pellet was centrifuged at 12000 rpms for 10 min at 4°C, and the supernatant was collected.
The cytoplasm and nuclear extracts were stored at -80°C until used.
Western Blotting: For western blot analysis, protein samples (50 μg per lane) were resolved using 12.5% SDS-PAGE, and transferred to nitrocellulose membranes, and incubated overnight with anti-p65 (Cell Signaling Technology, Danvers, MA). β-Actin and lamin (Bethyl, Montgomery, TX, USA) were used as loading controls for the cytosolic and nuclear fractions, respectively. After incubation with an HRP-conjugated secondary IgG (Sigma), the blots were developed using the ECL detection system (Pierce Biotechnology, Rockford, IL, USA). Band intensities were visualized by ChemiDoc using the Quantity One software (BioRad, Hercules, CA).
Reagents
The novel compound AMP-001-003 were designed and synthesized by Sci-Engi-Medco Solutions Inc (SEMCO). The drug doxorubicin was purchased from Sigma-Aldrich Biotechnology.
For all AMP-001-003/DOX combinational treatment, cancer cells were pretreated with AMP-001-003 before doxorubicin was added into the culture. All above micromolecular reagents were dissolved and saved according to manufacturer specifications. were purchased from the ATCC and grown in the RPMI-1640 medium supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% FBS, at 37°C and 5% CO 2 in humidified atmosphere. α-TOS (from Sigma) and AMP compounds were dissolved in water (AMP-001), ethanol (AMP-002) and DMSO (AMP-003) respectively, diluted in the complete medium to the final concentration of 60 µM and 30 µM, respectively, and added to cells at 0.1% of the solvent. 
Cell Viability Assay
Combination Index Calculations
Combination Indices were calculated using CompuSyn software, V. 1.0 (Biosoft, Cambridge, UK). Drug interactions were classified by determining a combination index (CI) recognized as the standard measure of combination effect based on the Chou-Talalay method. The CI values were obtained over a range of fractional cell kill levels (Fa) from 0.05 to 0.95 (5-95% cell kill). Based on the Chou-Talalay method (1,2,3,4), CI < 1 means synergism, CI = 1 means additivity, and CI > 1 is interpreted as antagonism.
Assessment of ROS Generation
Intracellular hydrogen peroxide was estimated using the fluorescent dye 2′7′-dichlorofluorescein diacetate (20 µM DCFDA; oxidized by hydrogen peroxide to DCF). A-549 and PC3 cells (10 5 ) were seeded in 24-well plates, treated with the drugs as above, and ROS formation was over time detected by a fluorescence plate reader (Infinite F200 PRO, Sunrise, Tecan, Männedorf, Swiss).
Assessment of Cathepsin B Activity.
Media and cells were harvested and processed as described previously 12 
Fluorescent Microscopy
A-549 and PC3 cells were placed in 6-well plates at 3×10 5 per well on glass coverslip. The cells were allowed to attach overnight and then incubated 24 h with α-TOS (60 μm), or AMP compounds (30 µM). After treatment, cells were resuspended in 2 ml RPMI-1640 medium with 5 μg/ml acridine orange (AO) and Hoechst (10 µg/ml) incubated at 37°C for 15 min, mounted on slides with Vectashield (Vector Laboratories) and viewed in a fluorescence microscope (Zeiss, Axiocam MRc5, magnification × 60).
Subcellular Fractionation and Western Blot Analysis
A-549, MDA-MB-231 and PC3 cells (3×10 5 per well in 6-well plates) were treated with α-TOS (60µM) and AMP compounds (30 µM) for 180 min, harvested, and the pellet re-suspended in the digitonin cell permebilization buffer (Trevigen, Gaithersburg, MD). The supernatant containing the cytosolic fraction was collected. The remaining pellet (organelle fraction) was lysed in the RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4,1 µg/ml protease inhibitors).
For western blot analysis, protein samples (50 µg per lane) were resolved using 12.5% SDS-PAGE, and transferred to nitrocellulose membranes, and incubated overnight with anti-caspase-9, anti-caspase-3 and anti-AIF (Cell Signaling Technology). β-Actin (Bethyl, Montgomery, TX, USA) were used as loading controls. After incubation with an HRP-conjugated secondary IgG (Sigma), the blots were developed using the ECL detection system (Pierce Biotechnology, Rockford, IL, USA). Band intensities were visualized by ChemiDoc using the Quantity One software (BioRad).
Transmission Electron Microscopy (TEM)
The treated cells were fixed in ice-cold 2% glutaraldehyde, scraped from the plates and postfixed in 1% osmium tetroxide with 0.1% potassium ferricyanide, dehydrated through a graded series of ethanol (30%-100%), and embedded in Epon-812 monomer and polymerized. Ultrathin sections were cut with a diamond knife mounted in a Reichart ultramicrotome, contrasted with uranyl acetate and lead citrate, and examined in a Hitachi HT7700 transmission electron microscope operated at 120 kV 26 . 
In Vivo Xenograft Assay
Immunohistochemical Staining
The xenograft tumor slides were incubated with the following primary antibodies: anti-CD31 was purchased from ABclonal and anti-Ki67 from Cell Signaling Technology (USA). Anti-rabbit or anti-mouse peroxidase-conjugated secondary antibody (ABclonal) and diaminobenzidine colorimetric reagent solution purchased from Dako (Carpinteria, CA) were used. The staining processes were according to standard methods.
Cardiotoxicity Assay
The data were collected from Ionic Transport Assays Inc. In brief, the adult human Cells were plated into 6 well plates that percolated with 0.1% gelatin. This was defined as culture day 1 for the purpose of this study. Cell plating media was changed at day 3 to cell maintenance media and cell maintenance media subsequently was changed three times a week. Day 5-7 cells were re-suspended with trypsin and re-plated as desired density (>10,000) at 96 well plate which percolated with 0.1% gelatin. were used to analyze data. According best-fit values were used to obtain IC-50. DMSO concentrations less than 1% had no effect on cell viability
Statistical Analysis
All experiments were performed at least three times. Data are presented as means ± SD.
All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad, SanDiego, CA).
One-way ANONVA and Student's t-test were applied to determine statistical significance. A value of p<0.05 was considered statistically significant.
Results
Synthesis of AMP-001, 002 and 003
The general synthesis of cathepsin B cleavable peptide conjugation with pegylated apoptogen and/or other apoptogens is accomplished through Fmoc chemistry to protect N end of peptide with Boc and then couple it with tocopherol derivatives using DCC in DMF. This was further cleaved by TFA and purified using HPLC method. Cathepsin cleavable compounds have been synthesized using the proprietary peptide synthesis technology. In brief, dipeptide valine-citrulline was synthesized using a microwave peptide synthesizer. All the details of experimental procedures and analytical data are described as reported earlier 27 and also in the published patent 12 . Scheme 1 shows the structures and main analytical characterization data on AMP-001/002 and 003.
Cytotoxicity of AMP-001-003 in Cancer Cell Lines
Cytotoxicity of AMP-001-003 was investigated in a variety of cancer cells including TNBC cells (MDA-MB-231, MCF-7, 4T1), gastric cancer cells (MGC-803, SGC-7091), lung (A549), normal breast epithelial cells (MCF-10A) and cardiomyocytes are shown in Table 1 . Cancer cells were treated with different concentrations of AMP-001-003 in vitro for 72 hours and cell viability was detected using MTT assay. In general, the range of IC-50 falls into early micromolar range which is similar to many FDA approved chemotherapeutics and the parent compound tocopheryl succinate (-TOS) 22 . The type of cell death induction was also measured using Annexin V and PI staining of the cells. The potential cytotoxicity of AMP-001/003 was also measured using the same method described above and the results showed that IC-50 values of AMP-001/003 in normal breast epithelial cells (MCF-10A) and in induced pluripotent stem cells cardiomyocytes (iPSC) are 15-20 times higher compared to cancer cells indicating the selectivity of AMP-001/003 to cancer cells. The selectivity of AMP-001/002 was also assessed through the uptake of drugs by Cathepsin B positive cancer cells Vs normal epithelial breast cells MCF-10A and the consequent differential cell death. Table 1 B 
Synergy of AMP-001-002 with Doxorubicin and Paclitaxel
The primary anticipated function of AMP-001-003 was to see if they synergize with the frontline chemotherapy such as doxorubicin or paclitaxel, particularly for treating TNBC patients. In general, synergistic effect is measured through combination index (CI) calculations [28] [29] (Fig 1 B) .
AMP-001 and AMP-002 were incubated with MDA-MB-231 and TNBC subsets of cells (BT549, WHIM12) at a fixed dose 20 M, varying doxorubicin concentration. The effective and significant reduction of IC-50 values for the combination of AMP-001/003 with doxorubicin is almost 6-10 times compared to individual drugs (Fig 1 A) . This suggests that the potency of combination outweighs individual ability of drugs to induce cell death. The synergistic effect was also measured by varying concentrations of each components to generate the isobologram. The ratio of AMP-001-003 was varied between 10-90 % for both doxorubicin and paclitaxel in experiments before calculating combination index. Table 1 B shows that all AMP-001-003 exhibited CI value less than 1.00 indicating that AMP-001-003 synergize with frontline chemotherapeutics such as doxorubicin and paclitaxel. In order to generate isobologram, experiments were designed to calculate ED50, ED75 and ED90 for both AMP-001, doxorubicin and combination. Isobologram 
Biological Targets for AMP-001-003.
Most tocopheryl derivatives produce reactive oxygen species (ROS) which presumably damage either lysozomes and/or mitochondria. In order to understand the potential mechanism of action and synergicity of AMP-001-003, kinetics of ROS formation was quantified using fluorescence DCFDA assay. Fig 2 shows the kinetics of ROS formation with 20 M AMP-00-003 for 6 hrs, with an initial surge of ROS around first 60 minutes followed with plateau pattern similar to -TOS. Next, morphology and lysosome perturbation were investigated using Hoechst and Acridine Orange (AO) staining in A543 and PC3 cells. at two different concentrations (25 and 50 μM) and at three different time points (6, 12 and 24 hrs). The expression levels of GAPDH and Beta-Actin were used as normalizing house-keeping genes. Ratio of Bax/Bcl2 for control cells is normalized to 1.0. The Bax to Bcl2 ratio has been greater than 1.0 is considered apoptotic effect, while the ratio of less than 1 is correlated to drug resistance. The quantification of Bax.Bcl2 ratio for AMP-001 ( Fig 5) clearly indicates that a time and dose dependent effect in MDA-MB-231 cancer cells treated with AMP-001 is greater than 1.00, while alpha-tocopherol (a negative control) shows no significant variation.
Pathways Involved in Sensitization of Tumor Cells:
A: NF-kB Pathway: The basic premise of AAAPT technology is to understand and probe specific pathways which are either activated or inhibited (e.g. survival pathways) based on the needs for cancer cells to survive the onslaught by treatments. The principle routes, amongst many is NF-kB pathway which is activated to retain the stemness of cancer cells, especially in cancer stem cells (CSCs) which escape cell death by chemotherapy. To determine whether AMP-001 has an effect on self-renewal of CSCs, mammosphere assay, a commonly used surrogate in vitro assay was used 37 . Two specific CSC enriched cancer cells were generated. The first is the MCF-10A cells overexpressing SRC oncogene, which has previously been shown to possess cancer stem activity and susceptible to the effects of metformin 36 . The second is mammary fat pad tumor-derived MDA-MB-231 cells (TMD-231), which we had previously demonstrated to have CSC property and metastasizes spontaneously to lungs upon mammary fat pad injection 36 . Cells were plated in a serum-free define media on ultralow adherent plates. The mammosphers were photographed a week after plating. AMP-001 treatment reduced mammosphere formation at 5 and 10 µM ( Fig 6) to greater than 50% reduction in mammosphere size as shown in Fig 6 E (expanded to 400X magnification).
4.1: Mechanism of NF-kB Inhibition:
NF-kB pathway inhibition was corroborated with the assessment of the trans-location of p65 protein from mitochondria to cytoplasm which was evaluated by Western Blotting analysis in TNBC cells after incubation with AMP-001/003 (20 M) for 24 hrs, or 4 hrs followed by TNF-alpha-induced NF-kB activation (Fig 7A-B Fig 7B, lane 1) , whereas AMP treatment reduced nuclear p65 ( Fig 7B, lanes 3-5) even in presence of alfa-TNF. In essence, the ratio of nuclear/cytoplasmic p65 fraction for AMP-001/003 decreases significantly compared to the untreated control or even with respect to positive control ( Fig 7C) and with respect to NF-kB activator alfa-TNF ( Fig 7D) . These results demonstrate that AMP-001/003 are capable of inhibiting survival machinery in cancer cells by inhibiting NF-kB activation. Similarly, we looked at the effect of AMP-001/003 on PARP which is hyperactivated in cancer cells by chemotherapy.
The dose dependent (0-40 M) incubation of AMP-001 with MDA-MB-231 cells and analysis by Western Blotting (Fig 8B) showed a clear cleavage of PARP at 89 KDa which suggests that PARP function may be inhibited. On the other hand, cell death pathway CD95 needs to be activated by AMP-001 in order to offset the downregulation of cell death pathway. Fas resistant MDA-MB-231 TNBC cells were treated with different concentrations of AMP-001 to assess the expression of CD95 (43 KDa) by Western Blotting (Fig. 8A) . The significant change in the intensity of the CD95 band in the isolated membrane fractions of treated cells indicates a possible translocation of CD95 receptor from cytosol to the surface of cell which triggers the apoptotic signal. In contrast, the untreated cells showed low intensity CD95 band.
5.0: Cardiotoxicity Assessment of AMP-001 Using Induced Pluripotent Stem Cells (iPSCs).
Generation of iPSCs by Ionic transport assays Inc (St Louis) is a convenient way to test the cardiotoxicity of compounds quickly using CCK-8 viability kits. As a known cardiotoxicity inducer, doxorubicin showed IC-50 around 9.6 M compared to > 250 M for AMP-001 and > 100 M for AMP-002. The photomicrographs of iPSCs indicate a significant cell death for doxorubicin compared to untreated control and AMP-001/002 (Fig 9 C Vs A-B-D) . Similarly, Sorafenib, another oncology drug also showed relatively higher toxicity at IC-50 (40 M) compared to AMP-001/002 ( Fig 9E Table) . Vitamin E was used as a positive control. It is to be noted that AMP-001/002 showed higher IC-50 values in cardiomyocytes (> 250 M), while it showed a potent toxicity on TNBC cells (32 M, 8 times less) indicating a selective cell death in cancer cells. Fig. 10 A shows a significant reduction in the bioluminescent signal correlated to tumor volume plotted as a percentage of tumor growth normalized at day 1 of injection ( Fig. 10B, p < 0.05) . The classic V curve confirms tumor regression in vivo, in the right direction although longer study of duration is warranted. No toxicity was observed (defined as significant weight loss, decreased mobility, grooming behavior or labored breathing) in the heart compared to untreated (Fig 10C, 3-4 ) assessed through histology ex vivo. Data are similar for kidney, liver and spleen sections (not shown). The relative cellularity of heart tissues Vs tumor tissue is significant, although the resolution needs improvement. Although, -tocopheryl succinate (-TOS) showed anti-tumor properties in vitro, studies in an immunocompetent mouse model showed that -TOS was not only ineffective at the published doses, but resulted in severe side effects due to lack of targetting 23 . -TOS also faced with water solubility, bioavailability and formulation issues demanding encapsulation of the drug into liposomes 30 . The lack of proof of targeting, particularly in vivo appears to be responsible for the lack of clinical product so far, for -TOS. That prompted us to incorporate a targeting vector which facilitates selectivity of the modified tocopheryl derivative. It has been well established that -TOS derivatives activated CD95 pathway sensitizing cancer cells for a better response from chemotherapy. However, ubiquitous activation of cell death pathway may induce unwanted systemic toxicity leading to side effects and hence, targeting is essential 13 . In order to achieve targeting, we have identified a tumor specific biomarker Cathepsin B which is overexpressed by cancer cells. Cathepsin B biomarker has been extensively used to target cancer cells commercially (e.g. 177 Lu-radiotherapy 20a , paclitaxel 20b , antibodies 20c ). Cathepsin cleavable technology is not new. However, it is needed to target cancer cells first before specific signal pathways are revamped to sensitize them for chemotherapy. Although, non-target sites express lower Cathepsin B, its overexpression in cancer cells makes target/non-target ratio high enough to mitigate the side effect risk for clinical application. For example, Cathepsin B overexpression was used as a tumor specific biomarker to image cancer sites delineating other low-positive Cathepsin B sites 19 . The rationale behind using cathepsin B cleavable linkers is based on the better safety profile of cathepsin B cleavable prodrugs doxorubicin 31a , paclitaxel 31b and antibodies 31c (Seattle Genetics) which are in clinical trials. The new design includes three types of AMP derivatives including a) AMP-001 which is pegylated to enhance the solubility of tocopheryl moiety which is basically hydrophobic and valine-citrulline peptide link which will be cleaved at citrulline link to release tocopheryl moiety, b) AMP-002 which is a small molecule with an ether linkage between tocopherol and the remaining part including valine citrulline linker and c) AMP-003 which is also a small molecule with an ester linkage between tocopherol OH and the remaining part (Scheme 1).
Small molecule design was proposed based on the potential commercial and manufacturing applications. The significant part of the current drug design is the cleavage of the pro-drug AMP-001-003 by the tumor specific enzyme Cathepsin B which releases tocopheryl cell death activating moiety in Cathepsin B positive cancer cells predominantly sparing normal cells.
The cytotoxicity for AMP-001-003 was measured by IC-50 values fall in the range M which are similar to parent -TOS and many FDA approved chemotherapeutics (see Table in ref 32) . It is to be noted that IC-50 for normal breast epithelial cells and cardiomyocytes are an order of magnitude (~ 50 to 100 times less) which may be attributed to the lack of presence of Cathepsin B, a tumor specific biomarker in normal breast cells. It means that the cell death potential of tocopheryl part was not released from prodrug which may explain the selectivity of AMP derivatives between normal and cancer cells.
The major objective of the drug design is to check if they sensitize CSCs, the low or nonresponsive tumor cells to standard chemotherapy such as doxorubicin. We measured the IC-50 of combination of AMP-001/003 with doxorubicin in various triple negative breast cancer cells (MDA-MB-231, WHIM 12, BT 549). Under the experimental conditions, IC-50 for standard doxorubicin was around 388 nM. However, when the cells were incubated with AMP-001 or 002 (20 M), there was a significant reduction of IC-50 for the combination from 388 nM level to 16-38 M level (~10 fold). This clearly indicates that AMP-001-002 enhance the potency of doxorubicin. This observation has a broader connotation that given the activation and inhibition of specific pathways by AMP derivatives (see mechanism of action), they evoke a better response from chemotherapy by reducing the eventual chemotherapeutic dose without compromising on efficacy, yet reducing the dose related toxicity. The change in IC-50 values was corroborated with photomicrographs of cell death (Fig 1, Supplementary) .
It is recommended that multiple dose combinations of drugs have to be tested in order to map out synergistic or antagonistic effects and differentiation of additive Vs synergistic effects.
The combination index is a standard method for two drug combinations to fix the ratio of doses at which synergicity occurs. The combination index was measured by generating isobologram for various doses of representative AMP-001 with doxorubicin or paclitaxel. The isobologram works by taking the effective concentration of each compound alone and drawing straight line between the axes. In this example (Fig 2B) , the calculated ED90 for AMP-001 was ~ 36 M and for doxorubicin ~2 M and a straight line was drawn between these two pints. If the combination value is less than 1.00 and below the line would be considered as synergistic, while CI value above 1.00 and above the line would be considered as antagonistic in nature. The point on the line would be additive. The data clearly indicate at all the three ED50/75/90 values, the CI is < 1.00 and below the line. This is quantitative data on the synergicity of AMP derivatives 29 .
Most tocopheryl derivatives are known to induce cell death through the generation of reactive oxygen species (ROS). Similarly, AMP-001-003 produced ROS, the kinetics of which followed a standard pattern raising the number of radicals initially (60-120 mins) followed by slow decline in about 6 hrs. However, cell death in cancer cells has to be correlated to downstream events such as release of apoptosis inducing factor (AIF-1) protein and Bax/Bcl2 expression. The biological targets involved for AMP-001/003 appear to be lysosomes and mitochondria. The uptake and distribution of acridine orange (AO) by cancer cells was assessed to determine the integrity of lysosome membrane permeabilization (LMP). In fact, acridine orange is a metachromatic lysosomotrophic agent that fluoresces red upon accumulation within the acidic environment of lysosomes and fluoresces green when located in the more alkaline cytosol or when bound to nuclear DNA. The induction of LMP leads to the release of acridine orange from the lysosomes out into the cytosol and nucleus. The reduction of red fluorescence upon incubation of AMP-001 or AMP-002 with PC3 or TNBC cells compared to control suggests that lysosome could be a potential target for ROS generated by AMP-001/003. It is significant that lysosomal membrane stability is related to the ability of ROS to overcome pro-survival autophagy 33 To determine whether AMP-001 has an effect on self-renewal of CSCs, we performed mammosphere assay, a commonly used surrogate in vitro assay to measure self-renewal 36 . We used two cell line models. The first is the MCF-10A cells overexpressing SRC oncogene, which has previously been shown to possess cancer stem activity and susceptible to the effects of metformin 23 . The second is mammary fat pad tumor-derived MDA-MB-231 cells (TMD-231), which we had previously demonstrated to have CSC property and metastasizes spontaneously to lungs upon mammary fat pad injection 36 . The reduction of number of mammospheres was evident at 5 or 10 M AMP-001 treatment. This effect of AMP-001 was similar to previously reported trans retinoic acid on stem cell activity of breast cancer cells including in TMD-231 cells 37 . NF-kB activation is correlated to the development of resistance to treatments. Hence, inhibition of NF-kB pathway selectively in cancer cells, potentially can make them susceptible to cell death.
Conventional NF-kB inhibitors (curcumin, JSH 23) have similar activity at much higher M range 38 and are not targeted to CSCs leading to unwanted side effects.
Potential Mechanism for Blocking Self-Renewal of CSCs. B). Inhibition of NF-kB Pathway:
NF-kB is a transcription factor linked to the control of apoptosis signaling. Pharmacological inhibition of NF-kB is known to inhibit proliferation of CSCs preferentially compared to bulk tumor population suggesting that NF-kB activity is critical for the survival of CSCs 38 NF-kB pathway may be one of the targets of AMP-001/002, which could partially explain the effects of the drugs on CSCs (Fig 6) . Deliberate NF-kB activation by alfa-TNF was nullified by AMP-001/003 indicating the potency of AMP-001/003 to inhibit NF-kB pathway. This result is very important since NF-kB activation is the survival pathway for CSCs and the controlled NF-kB inhibition is known to sensitize cells to chemotherapy 38 .
Sensitizing tumor cells to chemotherapy has an additional advantage that chemotherapy dose can be tuned down at the expense of sensitizing agent to yield a new formulation which will yield low toxicity due to low dose. The downregulation of cell death pathway CD95 is correlated to the development of resistance. Fas resistant MDA-MB-231 TNBC cells were treated with different concentrations of AMP-001 to assess the expression of CD95 (43 KDa) by Western blotting (Fig. 8 ). The significant change in the intensity of the CD95 band in the isolated membrane fractions of treated cells indicates a possible translocation of CD95 receptor from cytosol to the surface of cell which triggers the apoptotic signal. In contrast, the untreated cells showed low intensity CD95 band. Translocation of CD95 from cytosol to the membrane is a common observation for CD95 Trail synergy 31 which I further correlated to NF-kB inhibition (e.g. which influences the cellular sensitivity to the Fas death receptor pathway). Activation of CD95 pathway is important particularly, for CRCs and for CRCs where significant down regulation of CD95 is reported.
Improving the clinical performance of the current treatments for cancer in general and TNBC in particular is the main objective for sensitizing low-responsive tumor cells. Doxorubicin is one of the front-line treatments for TNBC patients. Doxorubicin treatment has been implicated in the hyperactivation of PARP in heart leading to cardiotoxiciy 41 . The inhibition of PARP by PARP inhibitors (e.g. Abbott ABT472) is known to sensitize tumor cells which are otherwise nonresponsive to doxorubicin, potentiated the effect of doxorubicin for tumor cells and ameliorated cardiotoxicity 42 . Dose dependent incubation of AMP-001 with MDA-MB-231 cells and analysis by Western blotting (Fig 8B) showed a clear cleavage of PARP at 89 KDa which suggests that PARP function may be inhibited which is correlated to the activation of pro-apoptotic caspases and subsequent apoptosis. This may also be related to sensitization of tumor cells by AMP-001.
The relative toxicity profiles of AMP-001/003 with respect to doxorubicin, particularly in cardiomyocytes and normal breast cells would help us to optimize the dose regimen in tumor animal models. Hence, induced pluripotent stem cell derived human cardiomyocytes (iPSC, Ionic Transport Assays, LLC) were treated with AMP-001/002 in vitro which showed high IC-50 value (> 200 M) for AMP-001/002, while doxorubicin is cardiotoxic at as low dose as at 9.6 M (Fig 9) .
At the same time, IC-50 values for AMP-001/002 are in 20-40 M range for cancer cells ( Table   27 1). The high differential IC-50 of AMP-001 between TNBC cells Vs cardiomyocytes (32 M Vs > 250 M respectively) may help to establish high target/non-target potential in vivo. It is to be noted that standard oncology drugs Sorafinib or doxorubicin are cardiotoxic at early M range compared to AMP-001/002. Efficacy and toxicity are the two main criteria for a successful clinical translation. Six-weekold female Nu/Nu rats (n = 8) were innoculated in the mammary fat pad with 5x10 6 MDA-MB-231 cells stably expressing firefly luciferase. Tumors were allowed to reach 100-150 mm 3 before i.p administration of AMP-001. For in vivo studies, six-week-old female Nu/Nu mice (n = 8) were innoculated in the mammary fat pad with 5x10 6 MDA-MB-231 cells stably expressing firefly luciferase. The treatment schedule for this experiment was AMP-001 monotherapy at 100 mg/Kg or 200 mg/Kg dose x 3 days x 2 weeks. Tumors were monitored by bioluminescence (IVIS 200, Perkin Elmer). No toxicity was detected as far as significant weight loss, decreased mobility, grooming behavior or labored breathing are concerned. Fig. 10A shows a significant reduction in the bioluminescent signal correlated to tumor volume plotted as a percentage of tumor growth normalized at day 1 of injection ( Fig. 10B , p < 0.05) compared to untreated control. The classic V curve confirms tumor regression "In vivo" and little adverse effect on heart ( Fig 10C) . Data are similar on kidney, liver and spleen sections (not shown). It is to be noted that low dose combination of AMP-001/002 (~10-20 M) is synergistic with doxorubicin in vitro, while high dose AMP-001 yielded tumor regression on its own with low off-target toxicity. Although, the final therapeutic dose 200mg/Kg seems to be high to make it commercially successful, the efficacy with no significant toxicity to non-target organs is a significant progress in the management of cancer disease. Also, AMP-001/003 are activating and inhibiting specific pathways to sensitize tumor cells, it is proposed to use them as a selective tumor sensitizer and hence, low dose of AMP-001/003 becomes a part of the combination formulation. Further studies on determination of maximum tolerable dose (MTD) which determines therapeutic index, leverage for tuning dose regime, extensive pharmacokinetic and pharmacodynamic aspects of drug development are in progress.
Conclusions
Since cancer is a group of diseases, several targets and pathways are involved in the progression of the disease. The combination of AAAPT leading molecule with a conventional chemotherapy brings multiple pathways involved in cancer cells which may help offset several dysregulated pathways for a potential synergicity.
In summary, the effects of novel vitamin E analogue AMP-001 is as a preclinical candidate is described. AMP-001 enhanced doxorubicin induced apoptosis in several cancer cells including TNBC cells via ROS-dependent mitochondrial apoptotic pathway, activation of cell death pathway (CD95) and inhibition of survival pathways (NF-kB and PARP). The efficacy of doxorubicin antitumor activity can be amplified by combining it with AMP-001, which would permit lower dose use in patients without affecting the positive clinical outcome. These effects are confirmed both in vitro and in vivo. Our current studies indicated that AMP-001 might be a potential candidate in synergetic with the existing FDA approved chemotherapeutic drugs for treatment of TNBC cancer which has limited number of treatments. Ultimately, the combination treatments success depends on how much low dose can be made effective in a clinical situation, reduced overall toxicity and improved patient compliance. Extending the synergicity of AMP-001 to other chemotherapeutics (e.g. Gemcitabine, Paclitaxel, Carboplatin, Avastin etc.) and other treatment modalities such as radiation, radionuclide therapy and immunotherapy may be significant contribution to cancer research. Further studies are planned to optimize the dose combination as to which one has higher efficacy and low toxicity compared to the existing treatments.
